PADI4 and rheumatoid arthritis: A range of reports demonstrate that genetic or pharmacological inhibition of PADI4 results in decreased extracellular histone citrullination and is protective against NET-associated tissue damage in a variety of pathological contexts, from rheumatoid arthritis and diabetes, to cancer metastasis and age-related tissue fibrosis21,26,53–55.